Capislow®:
a breakthrough ingredient that minimizes the appearance of new hair growth
Capislow® is a key ingredient in the PRESCRIBEDsolutions’ Noticeable Improvement, Hair Retardant. New hair growth can be affected by reducing keratinocytes, inhibiting the anagen phase of hair growth Capislow® is an extract from Larrea Divaricata, a shrub that grows in desert regions and contains high levels of lignanes. In studies (see figure to the right), Capislow®, after 28 days of treatment, reduced hair density by 26% and in some cases by as much as 50%; hair length was reduced by 11% and in some cases by as much as 30%; pilosity (hairiness) was reduced by 35% and in some cases by as much as 55%. (Study is available on request). |
Skin after 28 days of treatment
Source: Sederma Sa 2001 |
||||||||||||||||||
| <
Previous |
|||||||||||||||||||
Due to the advanced nature
of the high performance PRESCRIBED solutions products, the range,
is intended for use only under the supervision of physicians and medical personnel.
All rights reserved. The statements on this website have not been evaluated by
the FDA. The products are not intended to diagnose, treat, cure or prevent any
disease. PRESCRIBEDsolutions [CUSTOMIZED SKINCARE] is a registered
trademark of PRESCRIBEDsolutions, LLC. Capislow® is a registered
trademark of Sederma. Lumedia®
and Hylexin® are registered trademarks of Bremenn Research Labs. Pycnogenol,
FloraGLO and STAY-C 50 are trademarks of their respective owners. Synovea
HR is a registered trademark of Sytheon. Patent Pending. © PRESCRIBEDsolutions,
LLC 2001-2007. |